What VERACYTE, INC.'s executives and directors are doing with their own shares, from SEC Form 3/4/5 filings — separating what the filings state (awards, withholding, disclosed plans) from what only the pattern of dates shows.
| 3 months | 12 months | |
|---|---|---|
| Open-market buys | 0 | 0 |
| Sells | 13 | 50 |
| Total trades | 23 | 111 |
| 3 months | 12 months | |
|---|---|---|
| Acquired | 25,000 | 951,908 |
| Disposed | 88,476 | 641,652 |
| Net activity | −63,476 | +310,256 |
View rich charts and dive into the patterns of specific insiders — who is accumulating, who is winding down, and which sale explanations the filings actually support.
| Insider | Relation | Date | Transaction | Shares | Price | Value | Shares held |
|---|---|---|---|---|---|---|---|
| Wygant Jonathan | VP, Chief Accounting Officer | Oct 28 | Withheld — tax / exercise cost · F | −1,306 | $50.31 | −$65.7K | 41,920 |
| Holstein Jens | Director | Oct 27 | Open-market sale · S | −7,500 | $50.00 | −$375K | 27,471 |
| Holstein Jens | Director | Oct 27 | Exercise / conversion · M | +7,500 | $35.30 | +$265K | 34,971 |
| Eastham Karin | Director | Oct 27 | Open-market sale · S | −14,850 | $50.00 | −$743K | 10,247 |
| Eastham Karin | Director | Oct 27 | Exercise / conversion · M | +10,000 | $27.01 | +$270K | 25,097 |
| Bhanji Muna | Director | Oct 19 | Open-market sale · S | −1,864 | $43.70 | −$81.5K | 40,854 |
| Holstein Jens | Director | Sep 24 | Open-market sale · S | −7,500 | $47.00 | −$353K | 27,471 |
| Holstein Jens | Director | Sep 24 | Exercise / conversion · M | +7,500 | $35.30 | +$265K | 34,971 |
| Leite John | Global Chief Commercial Off | Sep 21 | Open-market sale · S | −4,015 | $40.00 | −$161K | 124,329 |
| Holstein Jens | Director | Sep 14 | Open-market sale · S | −5,000 | $40.95 | −$205K | 27,471 |
| McGuire Annie | EVP, General Counsel | Sep 04 | Open-market sale · S | −1,100 | $43.67 | −$48K | 131,160 |
| McGuire Annie | EVP, General Counsel | Sep 04 | Open-market sale · S | −2,154 | $42.79 | −$92.2K | 132,260 |
| Chambers Rebecca | Chief Financial Officer | Sep 04 | Open-market sale · S | −1,175 | $43.71 | −$51.4K | 166,025 |
| Chambers Rebecca | Chief Financial Officer | Sep 04 | Open-market sale · S | −2,477 | $42.81 | −$106K | 167,200 |
| Febbo Phillip G. | Chief Scientific & Med Officer | Sep 04 | Open-market sale · S | −2,705 | $43.66 | −$118K | 133,048 |
| Febbo Phillip G. | Chief Scientific & Med Officer | Sep 04 | Open-market sale · S | −10,405 | $42.89 | −$446K | 135,753 |
| Wygant Jonathan | VP, Chief Accounting Officer | Sep 02 | Withheld — tax / exercise cost · F | −1,361 | $44.88 | −$61.1K | 43,226 |
| McGuire Annie | EVP, General Counsel | Sep 02 | Withheld — tax / exercise cost · F | −3,215 | $44.88 | −$144K | 134,414 |
| Stapley Marc | Chief Executive Officer | Sep 02 | Withheld — tax / exercise cost · F | −8,782 | $44.88 | −$394K | 432,073 |
| Chambers Rebecca | Chief Financial Officer | Sep 02 | Withheld — tax / exercise cost · F | −3,603 | $44.88 | −$162K | 169,677 |
Loading...